Efforts to prospectively analyze the benefit associated with PSMA-PET vs traditional imaging include an ongoing prospective multicenter study (Primary Staging of Prostate Cancer: A Randomized Controlled Trial Comparing 18F-PSMA-1007 PET/CT to Conventional Imaging [PRISMA-PET]; NCT05123300) that plans to include 448 patients, randomized 1:1 to either traditional imaging or PSMA-PET/CT. Here, FOLH1 is linked to Familial prostate cancer.